1.40
+0.04(+2.94%)
Currency In USD
Address
210 East Grand Avenue
South San Francisco, CA 94080
United States of America
Phone
650 457 2700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
226
First IPO Date
October 11, 2018
| Name | Title | Pay | Year Born |
| David D. Chang | Co-Founder, President, Chief Executive Officer & Director | 1.06M | 1960 |
| Joshua A. Kazam | Co-Founder & Director | 54,000 | 1977 |
| Arie S. Belldegrun | Co-Founder & Executive Chairman | 685,292 | 1949 |
| Zachary J. Roberts | Executive Vice President of Research & Development and Chief Medical Officer | 714,747 | 1978 |
| Benjamin Beneski | Senior VP & Chief Technical Officer | 0 | 1977 |
| Earl Douglas | Senior Vice President, General Counsel, Compliance Officer & Corporate Secretary | 0 | 1963 |
| Geoffrey Parker | Executive VP & CFO | 0 | 1965 |
| Annie Yoshiyama | SVP & Corporate Controller | 0 | 1984 |
| Christine Cassiano | Executive VP, Chief Corporate Affairs & Brand Strategy Officer | 0 | N/A |
| Susan R. Lundeen | Chief People Officer | 0 | 1966 |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.